skip to main content

Endometrial Cancer — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardGynaecological CancersEndometrial CancerSCE Medical Oncology

A patient with recurrent endometrial cancer receives pembrolizumab, carboplatin and paclitaxel and has a partial response after six chemotherapy cycles. Toxicity has resolved and there is no progression. What systemic treatment should continue?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — Continue pembrolizumab alone, capped at 2 total years

TA1092 permits pembrolizumab with carboplatin-paclitaxel for untreated primary advanced or recurrent endometrial cancer and follows the trial/marketing-authorisation strategy of pembrolizumab continuation after chemotherapy. Pembrolizumab is stopped at 2 years, or earlier for progression or unacceptable toxicity. The recommendation is not restricted to dMMR disease, and cytotoxic chemotherapy is not continued for two years.

Reference: NICE TA1092 pembrolizumab with carboplatin and paclitaxel for advanced or recurrent endometrial cancer (Published August 2025): https://www.nice.org.uk/guidance/ta1092/chapter/1-Recommendations